Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 2/20 | 0.80 |
| ▸ | GSK3B | P49841 | 2/20 | 0.80 |
| ▸ | CCNA2 | P20248 | 7/20 | 0.73 |
| ▸ | CDK2 | P24941 | 7/20 | 0.73 |
| ▸ | CDK5 | Q00535 | 7/20 | 0.71 |
| ▸ | CDK5R1 | Q15078 | 7/20 | 0.71 |
| ▸ | MEN1 | O00255 | 5/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.71 |
| ▸ | NPC1 | O15118 | 4/20 | 0.71 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20142458 | 1.00 | GSK3A (0.80) | GSK3AGSK3BCCNA2CDK2CDK5 | |
| SCHEMBL20142463 | 0.94 | GSK3A (0.89) | GSK3AGSK3BCCNA2CDK2CDK5 | |
| SCHEMBL13633841 | 0.91 | CCNA2 (0.88) | GSK3AGSK3BCCNA2CDK2CDK5 | |
| SCHEMBL20142196 | 0.90 | GSK3A (0.81) | GSK3AGSK3BCCNA2CDK2CDK5 | |
| SCHEMBL20142068 | 0.89 | GSK3A (1.00) | GSK3AGSK3BCCNA2CDK2CDK5 | |
| SCHEMBL20141891 | 0.89 | GSK3A (0.80) | GSK3AGSK3BCCNA2CDK2CDK5 | |
| SCHEMBL20141893 | 0.89 | GSK3A (0.80) | GSK3AGSK3BCCNA2CDK2CDK5 | |
| SCHEMBL20142449 | 0.89 | GSK3A (0.80) | GSK3AGSK3BCCNA2CDK2CDK5 | |
| SCHEMBL25609556 | 0.88 | GSK3A (0.79) | GSK3AGSK3BCCNA2CDK2CDK5 | |
| SCHEMBL20142357 | 0.88 | GSK3A (0.79) | GSK3AGSK3BCCNA2CDK2CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018089902-A1 | DIAMINOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2018-05-17 | — | — | WO | claimed |
| EP-4139286-B1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AG (DE) | 2025-02-26 | — | — | EP | disclosed |
| US-11964953-B2 | Substituted aminothiazoles as DGKzeta inhibitors for immune activation | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-23 | — | — | US | disclosed |
| US-20230167078-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-01 | — | — | US | disclosed |
| US-20230167078-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-01 | — | — | US | disclosed |
| US-20230167078-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-01 | — | — | US | disclosed |
| US-20230139936-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-05-04 | — | — | US | disclosed |
| US-20230139936-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-05-04 | — | — | US | disclosed |
| WO-2018089902-A1 | DIAMINOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230139936-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | DGKZ, DGKA, DGKG | GSK3A 903/4885GSK3B 890/4885CCNA2 851/4885 |
| US-20230167078-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | DGKZ, DGKA, DGKG | GSK3A 903/4885GSK3B 890/4885CCNA2 851/4885 |
| US-11964953-B2 | Substituted aminothiazoles as DGKzeta inhibitors for immune activation | DGKZ, DGKA, DGKG | GSK3A 903/4885GSK3B 890/4885CCNA2 851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.